Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast Cancer.
Clinton YamNour AbuhadraRyan SunBeatriz E AdradaQing-Qing DingJason B WhiteElizabeth E RavenbergAlyson R ClaybornVicente ValeroDebasish TripathySenthilkumar DamodaranBanu K ArunJennifer K LittonNaoto Tada UenoRashmi K MurthyBora LimLuis BaezXiaoxian LiAman U BuzdarGabriel N HortobagyiAlistair M ThompsonElizabeth A MittendorfGaiane M RauchRosalind P CandelariaLei HuoStacy L MoulderJeffrey T ChangPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Further investigations will determine if metaplastic-like tumors should be treated more similarly to MpBC in the clinic. The 23% pCR rate in this study suggests that patients with MpBC should be considered for NAT. To improve this rate, a pathway analysis predicted enrichment of histone deacetylase (HDAC) and RTK/MAPK pathways in MpBC, which may serve as new targetable vulnerabilities.